Arthritis Advisory Committee

Arthritis Advisory Committee
Committee Meeting on June 21, 2011, from 8:30 a.m. to 4 p.m.

Agenda: On June 21, 2011, the committee will discuss the supplemental biologics license application 125319, ILARIS (canakinumab), Novartis Pharmaceuticals Corp., for the following proposed indication: ‘‘ILARIS is indicated for the treatment of gouty arthritis attacks. ILARIS has also been shown to extend the time to the next attack and reduce the frequency of subsequent attacks.’’